Listen to this article on the DDW Podcast: As public awareness about vaccines continues, there’s a population of people that is at increased risk of infection – the immunocompromised. Dr. Jeffery Stein, CEO of Cidara and an expert in viral diseases is passionate about the progress he’s… Read More
Featuring Specialty Spotlight: Immunotherapy, the magazine is available to download and read for free on the DDW App. Key features of the summer issue include: Why immunocompromised people are ‘forgotten’: Championing female leaders across drug discovery and development: Improving quality control for CAR T cell therapies, plus exclusive interviews and articles on… Read More
Suchita Gupta examines the immunochemistry reagents market post Covid-19. Immunohistochemistry (IHC) is referred to as the study of a branch of chemistry including the study of various components and functions of the immune system with the application of antigen & antibodies as chemical reagents. Read More
News round-up by DDW’s Reece Armstrong for 23-27 May UK investment plans, company appointments to drive strategy, and digital health platforms are some of the themes of this week’s news round-up. New £20m fund launches to support North West life sciences A new £20… Read More
Biotechnology company Calidi Biotherapeutics has been granted a US patent for its SuperNova (SNV) technology platform. Calidi’s SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent. The company aims to use it in combination with various immunotherapy agents, including blocking antibodies. The SNV platform is designed to shield oncolytic viral payloads from the… Read More
This 26-page DDW eBook, sponsored by The Jackson Laboratory, contains exclusive insight from industry experts on: How machine learning is currently used across different stages of cancer research Accelerating research: the path forward for treating rare cancers Immunotherapy challenges and the tools for research Why combination immunotherapies are one… Read More
DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector. Recently, the Food and Drug Administration (FDA) approved the first combination therapy… Read More
Ilya Pharma, a clinical stage immunotherapy company, has closed a €8.5 million funding round, which will be used to advance the company’s portfolio of three first-in-class immunotherapies for skin and mucosal diseases. The portfolio The active portfolio includes ILP100-Topical for treatment surgical wounds in diabetic,… Read More
Sonia Marsilio is an Associate Product Manager at Enzo. She explains how research tools enable scientists to accelerate immunotherapy. The growing, continuously evolving arsenal of cancer immunotherapies has changed the treatment landscape of many tumours. Dominating the space are the CAR T cell therapies, with CD19, BCMA, and CD22… Read More
In a clinical trial, Mount Sinai scientists gave immunotherapy to liver cancer patients before they received surgery and found that tumours died off significantly before surgery in a third of the patients, according to results reported in The Lancet Gastroenterology and Hepatology. The results The researchers… Read More
Dr Ian Walters, Chief Executive Officer and Director of Portage Biotech, shares how to find the path of least resistance through the immuno-oncology landscape. Our bodies are naturally trained to identify and remove abnormal cells, including those that are cancerous. Under normal circumstances, a person’s immune system detects proteins on the surface of cancer cells and targets them for elimination. The… Read More
Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy idecabtagene vicleucel, in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected… Read More
Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer. Context In a case study published in Nature Medicine, Sinai scientists reported a… Read More
Biotheus, a biotechnology company based in Zhuhai, China, with multiple clinical-stage assets under clinical development, has announced that its anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the United States Food and Drug Administration (FDA) for conducting clinical Phase II studies as part of an international multicentre clinical trial. … Read More
MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases. The acquisition This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions,… Read More
Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company,… Read More
